| Autor: |
Doman Al Yami, Majed Manea, Mohammed Al Aqeel, Nasser Saleh, Ibrahim Masoud, Majed Qasem, Almutairy, Abdulrhman Barakh, Banihumayyim, Mohammed Atig, Hamed Al Sagoor, Sauod Hussain, Salem Almotared, Dowas Saleh, Aboud Alshareef, Aboud Meshal, Alzmanan, Mohammed Nasser, Rashed Alkhumsan, Rashed Hadi, S. Aldaghreer, Nasser Manea, H. Alyami, Mohammed Abdullah, Hussin Al Rakh, Naif Ali, Mahdi Al Hutilah, Mana Abdullah, Mahdi Al Hutilah, Saleh Abdullah |
| Předmět: |
|
| Zdroj: |
Journal of Namibian Studies; 2023 Special Issue, Vol. 36, p203-216, 14p |
| Abstrakt: |
The development of new antibiotics is paramount in combating the escalating threat of antibiotic resistance, which poses significant challenges to global public health. However, this endeavor is hampered by regulatory and economic obstacles that impede the translation of scientific innovations into clinically effective therapies. Regulatory requirements, market dynamics, and reimbursement policies create barriers to antibiotic research and development, leading to a limited pipeline of novel antimicrobial agents. Addressing these challenges requires collaborative efforts from policymakers, regulators, pharmaceutical companies, and the healthcare community. Regulatory reforms, market-based incentives, and sustainable antibiotic use strategies are essential for expediting antibiotic development, stimulating investment, and preserving the effectiveness of existing antibiotics. This review examines the regulatory and economic challenges in antibiotic development and proposes strategies to overcome them, emphasizing the importance of innovation, stewardship, and global cooperation in safeguarding the efficacy of antibiotic therapies. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
